PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.11%
Negative revenue growth while MRVL stands at 4.84%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-46.33%
Negative gross profit growth while MRVL is at 4.67%. Joel Greenblatt would examine cost competitiveness or demand decline.
-73.29%
Negative EBIT growth while MRVL is at 79.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-73.29%
Negative operating income growth while MRVL is at 79.51%. Joel Greenblatt would press for urgent turnaround measures.
-59.46%
Negative net income growth while MRVL stands at 102.60%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-60.00%
Negative EPS growth while MRVL is at 102.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-59.38%
Negative diluted EPS growth while MRVL is at 102.50%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.44%
Share reduction while MRVL is at 2.70%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.83%
Reduced diluted shares while MRVL is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.44%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
-26.63%
Negative OCF growth while MRVL is at 70.17%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-38.91%
Negative FCF growth while MRVL is at 63.98%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
537.09%
10Y revenue/share CAGR above 1.5x MRVL's 22.84%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
187.74%
5Y revenue/share CAGR above 1.5x MRVL's 47.63%. David Dodd would look for consistent product or market expansions fueling outperformance.
153.80%
3Y revenue/share CAGR above 1.5x MRVL's 72.96%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
527.38%
10Y OCF/share CAGR above 1.5x MRVL's 15.80%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
72.42%
5Y OCF/share CAGR at 75-90% of MRVL's 92.70%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
32.48%
3Y OCF/share CAGR under 50% of MRVL's 239.31%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
446.85%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
7.70%
Positive 5Y CAGR while MRVL is negative. John Neff might view this as a strong mid-term relative advantage.
16.03%
Below 50% of MRVL's 105.61%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
431.45%
10Y equity/share CAGR above 1.5x MRVL's 113.69%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
282.19%
5Y equity/share CAGR above 1.5x MRVL's 130.01%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
125.30%
3Y equity/share CAGR above 1.5x MRVL's 61.39%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
13.94%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
-0.37%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-2.23%
Firm’s AR is declining while MRVL shows 8.41%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
22.95%
Inventory growth well above MRVL's 9.29%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-3.84%
Negative asset growth while MRVL invests at 0.56%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.98%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.06%
We’re deleveraging while MRVL stands at 1.35%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
12.73%
R&D growth drastically higher vs. MRVL's 1.10%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
No Data
No Data available this quarter, please select a different quarter.